According to FutureWise analysis the market for Radiotherapy in 2023 is US$ 6.64 billion, and is expected to reach US$ 10.04 billion by 2031 at a CAGR of 5.30%.
Improvements and further amendments in image-guided radiotherapy are propelling the market. The rising preference towards radiotherapy procedures for cancer treatment coupled with increasing usage of particle therapy for cancer diagnosis is spurring the market growth. Latest technological advancements in radiotherapy are expected to propel the market. Furthermore, rising incidences of cancer have expanded the market. According to the American Cancer Society, in 2020, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United States. The rise in research and development activities regarding cancer treatment launched by non-government and government organizations is expected to boost the market.
The market is classified into product type, type, application, end-user and region. Based on regions, North America dictates the market growth. Presence of prominent players and developed healthcare infrastructure is boosting the market in the region. Growing cases of cancer and favorable government policies are promoting adoption of radiotherapy, thus positively influencing the market. Asia-Pacific region is expected to be a lucrative region for manufacturers owing to a rapidly improving healthcare infrastructure and growing per capita income in emerging economies like China, Japan and India. In addition, favorable policies launched by the governments of these countries is expected to strengthen market position in the region.